FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: January 31, 2005 Estimated average burden hours per response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person * Holmes Scott A   2. Issuer Name and Ticker or Trading Symbol AMAG PHARMACEUTICALS INC. [AMAG] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director _____ 10% Owner __X__ Officer (give title below) _____ Other (specify below) SVP, Finance and Treasurer (Last) (First) (Middle) C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER STREET 3. Date of Earliest Transaction (Month/Day/Year) 06/03/2015 (Street) WALTHAM, MA 02451 4. If Amendment, Date Original Filed(Month/Day/Year) 06/05/2015 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person (City) (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1.Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 06/03/2015   M   3,750 (1) A $ 14.38 34,538 D   Common Stock 06/03/2015   M   12,891 (1) A $ 14.89 47,429 D   Common Stock 06/03/2015   M   5,875 (1) A $ 21.13 53,304 D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
	Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.		SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)

2. Conversion or Exercise Price of Derivative Security

3. Transaction Date (Month/Day/Year)

3A. Deemed Execution Date, if any (Month/Day/Year)

4. Transaction Code (Instr. 8)

5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)

6. Date Exercisable and Expiration Date (Month/Day/Year)

7. Title and Amount of Underlying Securities (Instr. 3 and 4)

8. Price of Derivative Security (Instr. 5)

9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)

10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)

11. Nature of Indirect Beneficial Ownership (Instr. 4)

Code

V

(A)

(D)

Date Exercisable

Expiration Date

Title

Amount or Number of Shares

Stock Option (Right to Buy)

$ 14.38

06/03/2015

M

3,750

(2)

09/12/2021

Common Stock

3,750 (1)

$ 0

1,250

D

Stock Option (Right to Buy)

$ 14.89

06/03/2015

M

12,891

(3)

06/25/2019

Common Stock

12,891 (1)

$ 0

17,109

D

Stock Option (Right to Buy)

$ 21.13

06/03/2015

M

5,875

(4)

02/27/2024

Common Stock

5,875 (1)

$ 0

12,925

D

Reporting Owners

Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
Holmes Scott A C/O AMAG PHARMACEUTICALS, INC. 1100 WINTER STREET WALTHAM, MA 02451			SVP, Finance and Treasurer

Signatures

Nancy R. Smith, attorney-in-fact		06/17/2015
**Signature of Reporting Person		Date

Explanation of Responses:

*	If the form is filed by more than one reporting person, see Instruction 4(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1)	This transaction was omitted from the reporting person's original Form 4. Following all of the transactions undertaken by the reporting person on June 3, 2015, the reporting person beneficially owned 53,304 shares of AMAG Pharmaceuticals, Inc. common stock.
(2)	This option vests and becomes exercisable in four equal annual installments on September 12, 2012, September 12, 2013, September 12, 2014 and September 12, 2015.
(3)	This option vests and becomes exercisable over four years from the grant date (June 25, 2012), with 25% vesting on the first anniversary of the grant date and the remainder vesting in equal quarterly installments over the next three years thereafter.
(4)	This option vests and becomes exercisable over four years from the grant date (February 27, 2014), with 25% vesting on the first anniversary of the grant date and the remainder vesting in equal quarterly installments over the next three years thereafter.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.